2010 marked the 10-year anniversary of the Sabin Vaccine Institute’s Human Hookworm Vaccine Initiative (HHVI), the world’s first and only product development partnership (PDP) aimed at developing a vaccine to combat human hookworm infection.
In the past 10 years, the HHVI has taken three single-antigen human hookworm vaccine candidates from bench-top research into process development, two vaccine candidates through pilot production, and one vaccine candidate into clinical trials. In the fall of 2010, the Netherlands Ministry of Foreign Affairs awarded a €5.9 million grant to the PDP in support of research and development of a vaccine to combat human hookworm infection.
In recognition of the tremendous milestones accomplished by the HHVI partners including Fundação Oswaldo Cruz, Instituto Butantan, James Cook University, the London School of Hygiene and Tropical Medicine, the National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention in China, and The George Washington University, Sabin President Dr. Peter Hotez was interviewed about the need for a human hookworm vaccine and gave his thoughts on milestones for the near future.
Click here to watch an audio slideshow featuring commentary from Dr. Hotez and photos from the PDPs clinical trial site in Americaninhas, Brazil; and to learn more about the HHVI’s resolve to eliminate human hookworm infection.







